IL5 and asthma: In conclusion, we offer an anti–IL-5Rα humanized Ab, 5R65.7, which more potently inhibits IL-5–dependent eosinophil proliferation and induces NK cell–mediated ADCC against eosinophils from patients with severe asthma, as compared with a benralizumab analogue.